Taigen Biopharmaceuticals Holdings Ltd

Taigen Biopharmaceuticals Holdings Ltd maintains a strong liquidity position, with a current ratio of 13.48, indicating a high ability to meet short-term obligations. The company's cash and equivalents amount to TWD 47,168,000, while its long-term debt is relatively low at TWD 49,217,000, resulting in a debt-to-equity ratio of 0.05. Despite a net cash position that is negative after subtracting total debt, the company's liquidity risk is assessed as medium.

The company's profitability is reflected in its return on equity (ROE) of 4.2% and return on assets (ROA) of 3.87%. These figures suggest that the company is generating returns, albeit at a moderate level, relative to its equity and total assets. The operating margin, calculated as operating income of TWD 68,660,000 on revenue of TWD 259,474,000, is 26.46%, which is a strong indicator of operational efficiency.

Taigen Biopharmaceuticals Holdings Ltd operates as a single-segment entity, with all revenue derived from its pharmaceuticals business. The company's geographic exposure is not disclosed in the available data, but its revenue concentration in a single business line suggests that its performance is closely tied to the success of its pharmaceutical products.

The company's growth trajectory is not explicitly outlined in the available data, but its revenue of TWD 259,474,000 and net income of TWD 45,178,000 indicate a stable financial position. The company's capital expenditure of TWD -4,505,000 suggests a reduction in investment in physical assets, which may reflect a focus on optimizing existing operations rather than expanding.

The risk assessment for Taigen Biopharmaceuticals Holdings Ltd indicates a low dilution risk, with no significant dilution sources identified in the available data. The company's liquidity risk is assessed as medium, primarily due to its net cash position being negative after subtracting total debt. The company's ESG scores, including a Social pillar score of 58.23 and a Governance pillar score of 64.93, suggest a moderate level of ESG performance.

Recent events and filings for Taigen Biopharmaceuticals Holdings Ltd are not detailed in the available data. However, the company's ESG controversies score of 100.00 indicates that it has not been involved in any significant ESG-related controversies.